- Fund is now closed and cannot accept any further subscriptions .
- Full deployment planned by end of tax year 2020/21.
- Deployed more than 65% of the funds in a diversed portfolio of 16 companies.
- More than 50% of investors' subscription has been fully deployed within 12-18 months.
EIS tax relief is very attractive for UK tax payers
You invest £50k
EIS gives you £15k tax relief from HMRC
EIS gives you £25k tax relief from HMRC
Investment now worth £100k
£50k profit
income tax relief £15k
performance incentive £10k
net profit £55k
Investment still worth £50k
£0 profit
income tax relief £15k
performance incentive £0
net profit £15k
Investment now worth £0
£50k loss
income tax relief £15k
loss relief £15,750 *
performance incentive £0
capital loss £19,250
* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees
*Tax relief depends on an individual’s circumstances and may change in the future.
- +History in grassroots science
We have a track record of nurturing and investing in emerging life science and tech companies – the o2h ventures team are leaders in the biotech community and have been involved as investors, holding various board/industry positions awe well as being engaged in grassroot scientific activity for over 20 years.
- +Evaluation
- +Access to scientific talents
- +Business model
our portfolio
Sorry, no results found with this search
- o2h Ventures, Third-Time Finalist in the Best EIS Manager Specialist at the Growth Investor Awards 2024 9 August, 2024
- Proud Partner of the 30th Anniversary Event by EISA, celebrating three decades of Enterprise Investment Schemes (EIS) 6 August, 2024
- From Biotech Chemist to Family Office to Biotech Pioneer – Sunil Shah’s Exciting Journey in Biotech 31 July, 2024